Incyte’s Ruxolitinib Cream Shows Promise for Vitiligo in Phase III Trials Published: May...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 17, 2021 at 11:12 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,741
    Likes Received:
    3
    via The use of ruxolitinib cream, Incyte’s investigational anti-inflammatory JAK inhibitor topical treatment, significantly improved facial vitiligo in adolescents and adults, according to topline results from two pivotal Phase III clinical trials.

    article source